



## **Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference**

February 18, 2020

SAN DIEGO--(BUSINESS WIRE)--Feb. 18, 2020-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9<sup>th</sup> Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 9:30 a.m. ET.

A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors" section of the company's website at <https://ir.gossamerbio.com>. A replay of the webcast will be archived on the company's website for 90 days following the presentation.

### **About Gossamer Bio**

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200218005064/en/>

Source: Gossamer Bio, Inc.

### **For Investors:**

Argot Partners  
212.600.1902  
[gossamerbio@argotpartners.com](mailto:gossamerbio@argotpartners.com)

### **For Media:**

Argot Partners  
David Rosen  
212.600.1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)